The ICC requires ≥ 10% blasts for most AML categories with defining genetics other than for BCR::ABL1 and mutated TP53, where ≥ 20% blasts distinguish it from CML, and for AML-MR where ≥ 20% blasts distinguish it from MDS. This evidence concerns the gene BCR and acute myeloid leukemia.